Published in Medical Letter on the CDC and FDA, January 11th, 2004
Currently in a confirmatory phase III clinical trial, StaphVAX is the company's investigational vaccine that is designed to prevent Staphylococcus aureus blood stream infections.
Nabi Biopharmaceuticals continues to make progress towards the manufacture of StaphVAX consistency lots at Cambrex Bio Science, Inc., to support the license application with the European Union planned for the end of 2004.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.